{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:17:13Z","timestamp":1791908233900,"version":"4.3.4"},"reference-count":95,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>The <jats:italic>PPARG<\/jats:italic> gene encodes a member of a nuclear receptor superfamily known as peroxisome proliferator-activated gamma (PPAR\u03b3). PPAR\u03b3 plays an essential role in adipogenesis, stimulating the differentiation of preadipocytes into adipocytes. Loss-of-function pathogenic variants in <jats:italic>PPARG<\/jats:italic> reduce the activity of the PPAR\u03b3 receptor and can lead to severe metabolic consequences associated with familial partial lipodystrophy type 3 (FPLD3). This review focuses on recent scientific data related to FPLD3, including the role of PPAR\u03b3 in adipose tissue metabolism and the phenotypic and clinical consequences of loss-of-function variants in the <jats:italic>PPARG<\/jats:italic> gene. The clinical features of 41 <jats:italic>PPARG<\/jats:italic> pathogenic variants associated with FPLD3 patients were reviewed, highlighting the genetic and clinical heterogeneity observed among 91 patients. Most of them were female, and the average age at the onset and diagnosis of lipoatrophy was 21 years and 33 years, respectively. Considering the metabolic profile, hypertriglyceridemia (91.9% of cases), diabetes (77%), hypertension (59.5%), polycystic ovary syndrome (58.2% of women), and metabolic-dysfunction-associated fatty liver disease (87,5%). We also discuss the current treatment for FPLD3. This review provides new data concerning the genetic and clinical heterogeneity in FPLD3 and highlights the importance of further understanding the genetics of this rare disease.<\/jats:p>","DOI":"10.3389\/fendo.2024.1394102","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T04:30:26Z","timestamp":1727411426000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Familial partial lipodystrophy resulting from loss-of-function PPAR\u03b3 pathogenic variants: phenotypic, clinical, and genetic features"],"prefix":"10.3389","volume":"15","author":[{"given":"Reivla Marques Vasconcelos","family":"Soares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique Alvares","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julliane Tamara Ara\u00fajo de Melo","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josivan Gomes","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12051122","article-title":"Familial partial lipodystrophy\u2014Literature review and report of a novel variant in PPARG expanding the spectrum of disease-causing alterations in FPLD3","volume":"12","author":"Rutkowska","year":"2022","journal-title":"Diagnostics"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2466","article-title":"The diagnosis and management of lipodystrophy syndromes: A multi-society practice guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/J.BBALIP.2019.02.002","article-title":"Gene-gene and gene-environment interactions in lipodystrophy: Lessons learned from natural PPAR\u03b3 mutants","volume":"1864","author":"Broekema","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1186\/S13098-016-0140-X","article-title":"Clinical and laboratory data of a large series of patients with congenital generalized lipodystrophy","volume":"8","author":"Lima","year":"2016","journal-title":"Diabetol Metab Syndr"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S130810","article-title":"Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges","volume":"10","author":"Chiquette","year":"2017","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/S13098-017-0280-7","article-title":"High prevalence of Berardinelli-Seip Congenital Lipodystrophy in Rio Grande do Norte State, Northeast Brazil","volume":"9","author":"De Azevedo Medeiros","year":"2017","journal-title":"Diabetol Metab Syndr"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0199052","article-title":"Causes of death in patients with Berardinelli-Seip congenital generalized lipodystrophy","volume":"13","author":"Lima","year":"2018","journal-title":"PloS One"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S206053","article-title":"Familial partial lipodystrophy (FPLD): Recent insights","volume":"13","author":"Bagias","year":"2020","journal-title":"Diabetes Metab Syndrome Obes"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2021.104071","article-title":"Familial partial lipodystrophy syndromes","volume":"50","author":"Fern\u00e1ndez-Pombo","year":"2021","journal-title":"Presse Medicale"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2016.102","article-title":"Clinical Utility Gene Card for: Familial partial lipodystrophy","volume":"25","author":"J\u00e9ru","year":"2016","journal-title":"Eur J Hum Genet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.dsx.2014.09.015","article-title":"PPAR gamma gene - A review","volume":"9","author":"Janani","year":"2015","journal-title":"Diabetes Metab Syndrome: Clin Res Rev"},{"key":"B12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1515\/hmbci-2014-0033","article-title":"PPAR\u03b3 mutations, lipodystrophy and diabetes","volume":"20","author":"Astapova","year":"2014","journal-title":"Horm Mol Biol Clin Investig"},{"key":"B13","unstructured":"The organization, promoter analysis, and expression of the human PPARg gene*\n            FajasL\n            AuboeufD\n            Rasp\u00e9E\n            SchoonjansK\n            LefebvreA-M\n            SaladinR\n          1997"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/ENDO.142.10.8458","article-title":"Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding","volume":"142","author":"Escher","year":"2001","journal-title":"Endocrinology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0014-5793(98)01273-3","article-title":"PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter","volume":"438","author":"Fajas","year":"1998","journal-title":"FEBS Lett"},{"key":"B16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1101\/GAD.953802","article-title":"PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis","volume":"16","author":"Ren","year":"2002","journal-title":"Genes Dev"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.celrep.2018.10.035","article-title":"PPAR\u03b3\u03945, a naturally occurring dominant-negative splice isoform, impairs PPAR\u03b3 Function and adipocyte differentiation","volume":"25","author":"Aprile","year":"2018","journal-title":"Cell Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a008417","article-title":"Adipogenesis","volume":"4","author":"Sarjeant","year":"2012","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/FENDO.2021.624112","article-title":"PPARgamma in metabolism, immunity, and cancer: unified and diverse mechanisms of action","volume":"12","author":"Hernandez-Quiles","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1146\/ANNUREV.BIOCHEM.77.061307.091829","article-title":"Fat and beyond: the diverse biology of PPARgamma","volume":"77","author":"Tontonoz","year":"2008","journal-title":"Annu Rev Biochem"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/J.TEM.2009.04.005","article-title":"Functional implications of genetic variation in human PPARgamma","volume":"20","author":"Jeninga","year":"2009","journal-title":"Trends Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/816856","article-title":"Review of the structural and dynamic mechanisms of PPAR\u03b3 Partial agonism","volume":"2015","author":"Kroker","year":"2015","journal-title":"PPAR Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13098-024-01387-9","article-title":"Case report: two novel PPARG pathogenic variants associated with type 3 familial partial lipodystrophy in Brazil","volume":"16","author":"da Silva","year":"2024","journal-title":"Diabetol Metab Syndrome"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90006-X","article-title":"Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor","volume":"79","author":"Tontonoz","year":"1994","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/24634","article-title":"Interdomain communication regulating ligand binding by PPAR-gamma","volume":"396","author":"Shao","year":"1998","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.tem.2014.04.001","article-title":"PPAR\u03b3 and the global map of adipogenesis and beyond","volume":"25","author":"Lefterova","year":"2014","journal-title":"Trends Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0303-7207(00)00211-2","article-title":"A PPARgamma mutant serves as a dominant negative inhibitor of PPAR signaling and is localized in the nucleus","volume":"162","author":"Berger","year":"2000","journal-title":"Mol Cell Endocrinol"},{"key":"B28","article-title":"Receptor Ativado por Proliferadores de Peroxissoma Gama (PPAR\u03b3): Estudo Molecular na Homeostase da Glicose, Metabolismo de Lip\u00eddeos e Abordagem Terap\u00eautica","volume-title":"Arq Bras Endocrinol Metab","author":"Tavares","year":"2007"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1515\/hmbci-2013-0036","article-title":"Adipose tissue and bone: Role of PPAR\u03b3 in adipogenesis and osteogenesis","volume":"15","author":"Kawai","year":"2013","journal-title":"Horm Mol Biol Clin Investig"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/NATURE05483","article-title":"Adipocytes as regulators of energy balance and glucose homeostasis","volume":"444","author":"Rosen","year":"2006","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/NRM2066","article-title":"Adipocyte differentiation from the inside out","volume":"7","author":"Rosen","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.16.7.3410","article-title":"Differentiation-dependent expression of the brown adipocyte uncoupling protein gene: regulation by peroxisome proliferator-activated receptor gamma","volume":"16","author":"Sears","year":"1996","journal-title":"Mol Cell Biol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1074\/JBC.272.45.28210","article-title":"Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators","volume":"272","author":"Martin","year":"1997","journal-title":"J Biol Chem"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1074\/JBC.M108213200","article-title":"Enhancement of the aquaporin adipose gene expression by a peroxisome proliferator-activated receptor gamma","volume":"276","author":"Kishida","year":"2001","journal-title":"J Biol Chem"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S1043-2760(01)00524-0","article-title":"ACRP30\/adiponectin: An adipokine regulating glucose and lipid metabolism","volume":"13","author":"Berg","year":"2002","journal-title":"Trends Endocrinol Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/35053000","article-title":"The hormone resistin links obesity to diabetes","volume":"409","author":"Steppan","year":"2001","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/NATURE05894","article-title":"Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance","volume":"447","author":"Odegaard","year":"2007","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3700","article-title":"Prospective functional classification of all possible missense variants in PPARG","volume":"48","author":"Majithia","year":"2016","journal-title":"Nat Genet"},{"key":"B39","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/79216","article-title":"The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes","volume":"26","author":"Altshuler","year":"2000","journal-title":"Nat Genet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.2006.00674.x","article-title":"A frameshift mutation in peroxisome-proliferator-activated receptor-\u03b3 in familial partial lipodystrophy subtype 3 (FPLD3; MIM 604367)","volume":"70","author":"Hegele","year":"2006","journal-title":"Clin Genet"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/J.CMET.2006.09.003","article-title":"Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance","volume":"4","author":"Agostini","year":"2006","journal-title":"Cell Metab"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2142-4","article-title":"Characterisation of non-obese diabetic patients with marked insulin resistance identifies a novel familial partial lipodystrophy-associated PPAR\u03b3 mutation (Y151C)","volume":"54","author":"Visser","year":"2011","journal-title":"Diabetologia"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2017.04.010","article-title":"Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy","volume":"72","author":"Akinci","year":"2017","journal-title":"Metabolism"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.P025437","article-title":"Clinical and molecular characterization of a severe form of partial lipodystrophy expanding the phenotype of PPAR\u03b3 deficiency","volume":"53","author":"Campeau","year":"2012","journal-title":"J Lipid Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.684182","article-title":"Case report: metreleptin treatment in a patient with a novel mutation for familial partial lipodystrophy type 3, presenting with uncontrolled diabetes and insulin resistance","volume":"12","author":"Lambadiari","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.14310\/horm.2002.1585","article-title":"Familial partial lipodystrophy type 3: a new mutation on the PPARG gene","volume":"14","author":"Lau","year":"2015","journal-title":"Hormones"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2014.06.006","article-title":"Biallelic mutations at PPARG cause a congenital, generalized lipodystrophy similar to the Berardinelli-Seip syndrome","volume":"57","author":"Dyment","year":"2014","journal-title":"Eur J Med Genet"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.112.300962","article-title":"Peroxisome proliferator-activated receptor-\u03b3 mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system","volume":"33","author":"Auclair","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/ng926","article-title":"Digenic inheritance of severe insulin resistance in a human pedigree","volume":"31","author":"Savage","year":"2002","journal-title":"Nat Genet"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1210\/JC.2005-2624","article-title":"Peroxisome proliferator-activated receptor-gamma C190S mutation causes partial lipodystrophy","volume":"92","author":"L\u00fcdtke","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1807","article-title":"Clinical case seminar: Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-\u03b3","volume":"92","author":"Monajemi","year":"2007","journal-title":"J Clin Endocrinol Metab. Endocrine Soc"},{"key":"B52","doi-asserted-by":"publisher","first-page":"99","DOI":"10.14341\/DM2015399-105","article-title":"Development of metabolic syndrome at a young age as a manifestation of familial partial lipodystrophy type 3 (PPARG mutation): The first description of its clinical case in Russia","volume":"18","author":"Sorkina","year":"2015","journal-title":"Diabetes Mellitus"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.2337\/DB17-1236","article-title":"A pharmacogenetic approach to the treatment of patients with PPARG mutations","volume":"67","author":"Agostini","year":"2018","journal-title":"Diabetes"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.830708","article-title":"Case report: A new peroxisome proliferator-activated receptor gamma mutation causes familial partial lipodystrophy type 3 in a Chinese patient","volume":"13","author":"Chen","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B55","unstructured":"Dominant negative mutations in human PPARg associated with severe insulin resistance, diabetes mellitus and hypertension\n            BarrosoI\n            Gurnell MF\n            CrowleyVE\n            AgostiniM\n            SchwabekJW\n            SoosMA\n          1999"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12837","article-title":"Novel peroxisome proliferator-activated receptor gamma mutation in a family with familial partial lipodystrophy type 3","volume":"84","author":"Miehle","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/J.DIABET.2012.02.012","article-title":"Vascular placental abnormalities and newborn death in a pregnant diabetic woman with familial partial lipodystrophy type 3: a possible role for peroxisome proliferator-activated receptor \u03b3","volume":"38","author":"Castell","year":"2012","journal-title":"Diabetes Metab"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-019-01462-y","article-title":"The novel loss of function Ile354Val mutation in PPARG causes familial partial lipodystrophy","volume":"57","author":"Padova","year":"2020","journal-title":"Acta Diabetol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2350-7-3","article-title":"Peroxisomal proliferator activated receptor-\u03b3 deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3)","volume":"7","author":"Francis","year":"2006","journal-title":"BMC Med Genet"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.12.3586","article-title":"Brief genetics report PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy","volume":"51","author":"Hegele","year":"2022","journal-title":"Diabetes"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1136\/JMG.2007.050567","article-title":"New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand","volume":"44","author":"L\u00fcdtke","year":"2007","journal-title":"J Med Genet"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1210\/JCEM.87.1.8290","article-title":"A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy","volume":"87","author":"Agarwal","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13061","article-title":"Familial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor -\u03b3 (PPARG) mutation, H449L: a comparison of people with this mutation and those with classic codon 482 Lamin A\/C (LMNA) mutations","volume":"33","author":"Demir","year":"2016","journal-title":"Diabetic Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/J.MOLMET.2018.12.005","article-title":"Natural helix 9 mutants of PPAR\u03b3 differently affect its transcriptional activity","volume":"20","author":"Broekema","year":"2019","journal-title":"Mol Metab"},{"key":"B65","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1507\/ENDOCRJ.EJ22-0140","article-title":"Clinical characteristics and efficacy of pioglitazone in a Japanese patient with familial partial lipodystrophy due to peroxisome proliferator-activated receptor \u03b3 gene mutation","volume":"70","author":"Iizaka","year":"2023","journal-title":"Endocr J"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1210\/ME.2009-0073","article-title":"Decreased PPAR\u03b3 Expression compromises perigonadal-specific fat deposition and insulin sensitivity","volume":"23","author":"Tsai","year":"2009","journal-title":"Mol Endocrinol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1210\/JCEM.84.1.5383","article-title":"Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety)","volume":"84","author":"Garg","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1210\/JENDSO\/BVAC155","article-title":"Phenotypic differences among familial partial lipodystrophy due to LMNA or PPARG variants","volume":"6","author":"Vasandani","year":"2022","journal-title":"J Endocr Soc"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1210\/JC.2018-02787","article-title":"Efficacy of metreleptin treatment in familial partial lipodystrophy due to PPARG vs LMNA pathogenic variants","volume":"104","author":"Sekizkardes","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/HUMU.22981","article-title":"HGVS recommendations for the description of sequence variants: 2016 update","volume":"37","author":"den Dunnen","year":"2016","journal-title":"Hum Mutat"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/GIM.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/NMETH.2890","article-title":"MutationTaster2: mutation prediction for the deep-sequencing age","volume":"11","author":"Schwarz","year":"2014","journal-title":"Nat Methods"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/BIOINFORMATICS\/BTAB051","article-title":"Mutalyzer 2: next generation HGVS nomenclature checker","volume":"37","author":"Lefter","year":"2021","journal-title":"Bioinformatics"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/NAR\/GKAD989","article-title":"CADD v1.7: using protein language models, regulatory CNNs and other nucleotide-level scores to improve genome-wide variant predictions","volume":"52","author":"Schubach","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/J.AJHG.2016.08.016","article-title":"REVEL: an ensemble method for predicting the pathogenicity of rare missense variants","volume":"99","author":"Ioannidis","year":"2016","journal-title":"Am J Hum Genet"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3390\/CELLS12050725","article-title":"Clinical spectrum of LMNA-associated type 2 familial partial lipodystrophy: A systematic review","volume":"12","author":"Fernandez-Pombo","year":"2023","journal-title":"Cells"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1186\/1758-5996-4-40","article-title":"Body composition study by dual-energy x-ray absorptiometry in familial partial lipodystrophy: Finding new tools for an objective evaluation","volume":"4","author":"Valerio","year":"2012","journal-title":"Diabetol Metab Syndr"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/FMED.2023.1227188","article-title":"Fatty infiltration of the pancreas: a systematic concept analysis","volume":"10","author":"Mahyoub","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2356","article-title":"Fatty acid metabolism in patients with PPAR\u03b3 mutations","volume":"93","author":"Tan","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1152\/AJPCELL.00379.2020\/ASSET\/IMAGES\/LARGE\/AJ-ACEL210014F002.JPEG","article-title":"Adipose tissue inflammation and metabolic dysfunction in obesity","volume":"320","author":"Kawai","year":"2021","journal-title":"Am J Physiol Cell Physiol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000316893","article-title":"Human lipodystrophies: genetic and acquired diseases of adipose tissue","volume":"19","author":"Capeau","year":"2010","journal-title":"Endocr Dev Basel, Karger"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2007.12.008","article-title":"Interference with PPAR\u03b3 Function in smooth muscle causes vascular dysfunction and hypertension","volume":"7","author":"Halabi","year":"2008","journal-title":"Cell Metab"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/NRENDO.2014.115","article-title":"Pax-8-PPAR-\u03b3 fusion protein in thyroid carcinoma","volume":"10","author":"Raman","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.1.43","article-title":"Familial lipodystrophy associated with neurodegeneration and congenital cataracts","volume":"58","author":"Berger","year":"2002","journal-title":"Neurology"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/J.EXER.2021.108617","article-title":"The role of peroxisome proliferator-activated receptors in healthy and diseased eyes","volume":"208","author":"Escandon","year":"2021","journal-title":"Exp Eye Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS23179708","article-title":"The role of transcription factor PPAR-\u03b3 in the pathogenesis of psoriasis, skin cells, and immune cells","volume":"23","author":"Sobolev","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B87","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40618-018-0887-z","article-title":"Diagnosis and treatment of lipodystrophy: a step-by-step approach","volume":"42","author":"Ara\u00fajo-Vilar","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S11892-018-1100-7\/METRICS","article-title":"Update on therapeutic options in lipodystrophy","volume":"18","author":"Akinci","year":"2018","journal-title":"Curr Diabetes Rep"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/J.LFS.2010.08.002","article-title":"Differential modulatory effects of rosiglitazone and pioglitazone on white adipose tissue in db\/db mice","volume":"87","author":"Yang","year":"2010","journal-title":"Life Sci"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M800165-JLR200","article-title":"A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes","volume":"49","author":"Beysen","year":"2008","journal-title":"J Lipid Res"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.2337\/DIACARE.28.7.1547","article-title":"A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia","volume":"28","author":"Goldberg","year":"2005","journal-title":"Diabetes Care"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80243-6","article-title":"Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: Comparative subgroup analyses of glycemic control and blood lipid levels","volume":"25","author":"Olansky","year":"2003","journal-title":"Clin Ther"},{"key":"B93","unstructured":"Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor\n            SavageDB\n            TanGD\n            AceriniCL\n            JebbSA\n            AgostiniM\n            GurnellM"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2022.03.006","article-title":"Clinical effects of sodium-glucose transporter type 2 inhibitors in patients with partial lipodystrophy","volume":"28","author":"Bansal","year":"2022","journal-title":"Endocrine Pract"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.2337\/DC23-1614","article-title":"Efficacy and safety of glucagon-like peptide 1 agonists in a retrospective study of patients with familial partial lipodystrophy","volume":"47","author":"Foss-Freitas","year":"2024","journal-title":"Diabetes Care"}],"updated-by":[{"DOI":"10.3389\/fendo.2024.1508146","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000}}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1394102\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T07:43:45Z","timestamp":1733211825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1394102\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":95,"alternative-id":["10.3389\/fendo.2024.1394102"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1394102","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fendo.2024.1508146","asserted-by":"object"}]},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"article-number":"1394102"}}